Oncology · ChemotherapyRegulatory Approvalcommercialmid-term

FDA Approval Process Update for Capecitabine ANDA204345 by Dr. Reddy's

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/5/2026, 12:32:48 AM

Assessment confidence: 63% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of Dr. Reddy's ANDA for Capecitabine marks a significant move into the generic oncology market, which could disrupt existing pricing and market share dynamics for branded products. Portfolio teams must evaluate the potential impact on their strategies as competition increases. Regulatory context from FDA (FDA AP — CAPECITABINE (SUPPL)) supports the near-term read. Assessment grounded in 30 ranked evidence items (11 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of generic Capecitabine on market share and pricing strategies for existing oncology products. The strongest clinical anchor is A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Chemotherapy, 7 regulatory and 7 competitive items passed relevance filtering for Dr.

Competitive Pressure

The most relevant competitive pressure comes from Dr. Reddy's Sugammadex Sodium ANDA214236 Receives FDA Approval (Humanexa Signals) — entity match (dr reddy s). Secondary pressure from [Ad hoc announcement pursuant to Art.. This submission indicates Dr. Reddy's is entering the generic market for Capecitabine, potentially increasing competition against branded versions.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — CAPECITABINE (SUPPL) (FDA). Entity match (capecitabine); Regulatory pathway relevance (nda). The ongoing standard review process for the ANDA could influence the timeline for market entry and subsequent competitive landscape.

Key Risks

Elevated medium regulatory exposure for Dr. Reddy's could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The entry of a generic version of Capecitabine may lead to price erosion and loss of market share for existing branded therapies, affecting revenue projections.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
Upside for Dr. Reddy's may improve if Client and therapist experiences with the Processing of Positive Memories Technique (PPMT) in a randomized controlled trial: insights for protocol refinement. (PubMed) delivers favorable follow-through.
The landscape of drug delivery is undergoing a transformative shift. As demand for large-volume subcutaneous (SC) biologics continues to surge, the race to develop smarter, patient-centered combination drug products has never been more urgent.

What Would Change This Assessment

This becomes more urgent if Monitor the review timeline and any updates on approval status for ANDA204345.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — CAPECITABINE (SUPPL)
FDAhigh relevance
Entity match (capecitabine); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CAPECITABINE (SUPPL)
FDAhigh relevance
Entity match (capecitabine); Regulatory pathway relevance (nda)
FDA document
View source
Other | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Advancing Generic Drug Development: Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs - 08/27/2026
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Verified Clinical Benefit | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source

A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Met
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Electroacupuncture and Exercise for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Top-Down Attentional Control of Visual-Processing
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Dr. Reddy's Sugammadex Sodium ANDA214236 Receives FDA Approval
Humanexa Signalshigh relevance
Entity match (dr reddy s)
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
FDA Accepts NDA for Trabectedin by Apotex
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Sitagliptin and Metformin Hydrochloride Combination
Humanexa Signalsmedium relevance
Moderate corpus alignment
Cipla's Lenalidomide ANDA210435 Receives Abbreviated Approval from FDA
Humanexa Signalsmedium relevance
Moderate corpus alignment

Client and therapist experiences with the Processing of Positive Memories Technique (PPMT) in a randomized controlled trial: insights for protocol refinement.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Protocol for a cohort study: evaluating the effect of neoadjuvant immunochemotherapy on intraoperative remifentanil consumption during IoC2-guided anesthesia in elderly patients with esophageal cancer
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Migraine relief: Solutions from natural bioactive products of Traditional Chinese medicine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Subcutaneous drug delivery of high concentration antibody products - part 2: formulation, device options, and clinical bridging strategies for patient-centric commercial presentations.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Dr. Reddy's
Capecitabine
branded oncology products

Commercial impact

medium

The entry of a generic version of Capecitabine may lead to price erosion and loss of market share for existing branded therapies, affecting revenue projections.

Regulatory impact

medium

The ongoing standard review process for the ANDA could influence the timeline for market entry and subsequent competitive landscape.

What to watch

Monitor the review timeline and any updates on approval status for ANDA204345.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.